Suppr超能文献

医学研究委员会及新开发的恶性胶质瘤患者预后指数的验证:预后指数在常规临床实践中有多大用处?

Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

作者信息

Akman Fadime, Cooper Rachel A, Sen Mehmet, Tanriver Yildiray, Kentli Süleyman

机构信息

Department of Radiation Oncology, Dokuz Eylül University, Medical School, Izmir, Turkey.

出版信息

J Neurooncol. 2002 Aug;59(1):39-47. doi: 10.1023/a:1016353614525.

Abstract

Although different prognostic indices for malignant gliomas have been developed, their validity outside of clinical trials has not been widely tested. The aim of this study was to determine whether the Medical Research Council (MRC) brain tumour prognostic index was able to stratify patients for survival managed in routine practice, and secondly to compare the results with our newly developed prognostic score which included tumour grade and only 3 prognostic groups. The MRC and the new prognostic index were calculated for a group of 119 adult patients with malignant glioma managed by surgical resection/biopsy and post-operative radiotherapy. For the MRC and new score, 6 and 3 prognostic groups were defined, respectively. For all patients median survival was 11 (2-66) months. The overall survival rate at 12 and 24 months were 43% and 18%, respectively. The MRC median and two-year survival rates were 14 months and 26% for a score of 1-10, 14 months and 27% for a score of 11-15, 13 months and 22% for a score of 16-20, 8 months and 10% for a score of 21-25, 8 months and 0% for those scoring 26-33. There was only one patient in the 34-38 group. For the new prognostic index, median and two-year survival rates were respectively 16 and 26%; 12 and 23%; 8 and 7% for the good, intermediate and poor prognostic groups. Both indices were significant factors for survival in univariate analysis (MRC index, p = 0.0089, new index p = 0.0002), but not in multivariate analysis. Both the MRC and our newly devised prognostic score were able to separate patients into good and poor prognostic groups, which may aid in treatment decisions, although there was less differentiation between the MRC groups especially over the first year. Both scores use routinely available factors. However, inclusion of tumour grade in the new score may be an advantage over the MRC index.

摘要

尽管已经开发出了不同的恶性胶质瘤预后指数,但它们在临床试验之外的有效性尚未得到广泛检验。本研究的目的是确定医学研究委员会(MRC)脑肿瘤预后指数能否对常规治疗中的患者生存情况进行分层,其次是将结果与我们新开发的预后评分进行比较,新评分包括肿瘤分级且仅分为3个预后组。对一组119例接受手术切除/活检及术后放疗的成年恶性胶质瘤患者计算了MRC和新的预后指数。对于MRC和新评分,分别定义了6个和3个预后组。所有患者的中位生存期为11(2 - 66)个月。12个月和24个月时的总生存率分别为43%和18%。MRC评分1 - 10分的患者中位生存期和两年生存率分别为14个月和26%,11 - 15分的患者为14个月和27%,16 - 20分的患者为13个月和22%,21 - 25分的患者为8个月和10%,26 - 33分的患者为8个月和0%。34 - 38分组中只有1例患者。对于新的预后指数,良好、中等和不良预后组的中位生存期和两年生存率分别为16个月和26%;12个月和23%;8个月和7%。在单因素分析中,两个指数都是生存的显著因素(MRC指数,p = 0.0089,新指数p = 0.0002),但在多因素分析中并非如此。MRC和我们新设计的预后评分都能够将患者分为预后良好和不良的组,这可能有助于治疗决策,尽管MRC分组之间的差异较小,尤其是在第一年。两个评分都使用常规可得的因素。然而,新评分中纳入肿瘤分级可能是相对于MRC指数的一个优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验